Hubei Biocause Pharmaceutical (000627) — Net Asset Quality Index
Hubei Biocause Pharmaceutical (000627) has a Net Asset Quality Index of 12.6% as of September 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥285.15 Billion minus total liabilities of CN¥249.15 Billion yields net assets of CN¥36.00 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See operational self-sufficiency of Hubei Biocause Pharmaceutical to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hubei Biocause Pharmaceutical Net Asset Quality Index Over Time (2000–2023)
This chart shows how Hubei Biocause Pharmaceutical's Net Asset Quality Index has evolved across 24 annual periods from 2000 to 2023. As of September 2024, the index stands at 12.6%, representing net assets of CN¥36.00 Billion against total assets of CN¥285.15 Billion CNY. Explore 000627 cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Hubei Biocause Pharmaceutical (2000–2023)
The table below presents the year-by-year Net Asset Quality Index for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hubei Biocause Pharmaceutical stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 11.1% | CN¥33.63 Billion | CN¥301.94 Billion | CN¥268.30 Billion | ▼ -0.9 pp |
| 2022 | 12.0% | CN¥34.60 Billion | CN¥288.60 Billion | CN¥254.00 Billion | ▼ -2.2 pp |
| 2021 | 14.2% | CN¥37.47 Billion | CN¥263.90 Billion | CN¥226.43 Billion | ▼ -0.2 pp |
| 2020 | 14.4% | CN¥34.59 Billion | CN¥239.40 Billion | CN¥204.81 Billion | ▼ -2.3 pp |
| 2019 | 16.7% | CN¥34.35 Billion | CN¥205.27 Billion | CN¥170.92 Billion | ▲ +2.1 pp |
| 2018 | 14.6% | CN¥26.01 Billion | CN¥178.25 Billion | CN¥152.24 Billion | ▼ -4.4 pp |
| 2017 | 19.0% | CN¥26.70 Billion | CN¥140.42 Billion | CN¥113.71 Billion | ▲ +1.7 pp |
| 2016 | 17.3% | CN¥20.40 Billion | CN¥117.88 Billion | CN¥97.48 Billion | ▼ -56.7 pp |
| 2015 | 74.0% | CN¥1.78 Billion | CN¥2.41 Billion | CN¥625.50 Million | ▲ +3.4 pp |
| 2014 | 70.7% | CN¥1.49 Billion | CN¥2.11 Billion | CN¥618.76 Million | ▲ +4.1 pp |
| 2013 | 66.6% | CN¥1.44 Billion | CN¥2.16 Billion | CN¥720.71 Million | ▼ -7.9 pp |
| 2012 | 74.5% | CN¥1.54 Billion | CN¥2.06 Billion | CN¥527.37 Million | ▼ -0.6 pp |
| 2011 | 75.1% | CN¥1.41 Billion | CN¥1.88 Billion | CN¥469.47 Million | ▼ -6.0 pp |
| 2010 | 81.1% | CN¥1.60 Billion | CN¥1.98 Billion | CN¥374.25 Million | ▲ +8.0 pp |
| 2009 | 73.0% | CN¥1.57 Billion | CN¥2.16 Billion | CN¥581.29 Million | ▼ -3.4 pp |
| 2008 | 76.4% | CN¥1.51 Billion | CN¥1.98 Billion | CN¥466.75 Million | ▲ +11.0 pp |
| 2007 | 65.4% | CN¥866.03 Million | CN¥1.32 Billion | CN¥458.52 Million | ▲ +3.4 pp |
| 2006 | 62.0% | CN¥723.71 Million | CN¥1.17 Billion | CN¥443.66 Million | ▼ -5.2 pp |
| 2005 | 67.2% | CN¥731.23 Million | CN¥1.09 Billion | CN¥356.70 Million | ▲ +0.3 pp |
| 2004 | 66.9% | CN¥723.91 Million | CN¥1.08 Billion | CN¥357.41 Million | ▲ +1.1 pp |
| 2003 | 65.9% | CN¥718.75 Million | CN¥1.09 Billion | CN¥372.22 Million | ▼ -4.6 pp |
| 2002 | 70.4% | CN¥768.02 Million | CN¥1.09 Billion | CN¥322.39 Million | ▼ -6.7 pp |
| 2001 | 77.1% | CN¥762.99 Million | CN¥989.09 Million | CN¥226.09 Million | ▲ +10.1 pp |
| 2000 | 67.1% | CN¥594.52 Million | CN¥886.33 Million | CN¥291.81 Million | — |